{
  "source": "PA-Notification-Inlyta.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1046-13\nProgram Prior Authorization/Notification\nMedication Inlyta® (axitinib)\nP&T Approval Date 4/2012, 8/2012, 7/2013, 8/2014, 8/2015, 7/2016, 7/2017, 7/2018,\n9/2019, 9/2020, 9/2021, 9/2022, 9/2023, 9/2024\nEffective Date 11/17/2024\n1. Background:\nInlyta (axitinib) is a kinase inhibitor indicated for the treatment of advanced renal cell\ncarcinoma (RCC) after failure of one prior systemic therapy. It is also indicated in\ncombination with either avelumab or pembrolizumab for the first-line treatment of patients\nwith advanced RCC. The NCCN (National Comprehensive Cancer Network) recommends the\nuse of Inlyta for treatment of unresectable, metastatic, or recurrent salivary gland tumors and\nfollicular, oncocytic, and papillary carcinomas. The NCCN also recommends Inlyta as\npreferred therapy in combination with pembrolizumab for treatment of alveolar soft part\nsarcoma (ASPS) and as first-line treatment of relapsed or stage IV renal cell carcinoma.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age\nof 19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Inlyta will be approved based on the following criterion:\n(1) Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Renal Cell Carcinoma\n1. Initial Authorization\na. Inlyta will be approved based on one of the following criteria:\n(1) Both of the following:\n(a) Diagnosis of advanced renal cell carcinoma\n© 2024 UnitedHealthcare Services, Inc.\n1\n-AND-\n(b) One of the following:\ni. Patient h",
    " based on one of the following criteria:\n(1) Both of the following:\n(a) Diagnosis of advanced renal cell carcinoma\n© 2024 UnitedHealthcare Services, Inc.\n1\n-AND-\n(b) One of the following:\ni. Patient has failed one prior systemic therapy\n-OR-\nii. Inlyta will be used in combination with Bavencio (avelumab) or\nKeytruda (pembrolizumab)\n-OR-\n(2) Diagnosis of relapsed or stage IV renal cell carcinoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Inlyta will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Inlyta therapy\nAuthorization will be issued for 12 months.\nC. Thyroid Carcinoma\n1. Initial Authorization\na. Inlyta will be approved based on all of the following criteria:\n(1) One of the following diagnosis:\n(a) Follicular Carcinoma\n(b) Oncocytic Carcinoma\n(c) Papillary Carcinoma\n-AND-\n(2) Disease is one of the following:\n(a) Recurrent and unresectable\n(b) Persistent\n(c) Metastatic\n-AND-\n(3) Not amenable to radioactive iodine (RAI) treatment\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2\n2. Reauthorization\na. Inlyta will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Inlyta therapy\nAuthorization will be issued for 12 months.\nD. Salivary Gland Tumor\n1. Initial Authorization\na. Inlyta will be approved based on both of the following criteria:\n(1) Diagnosis of salivary gland tumor\n-AND-\n(2) Disease is one of the following:\n(a) Recurrent\n(b) Unresectable\n(c) Metastatic\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Inlyta will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Inlyta therapy\nAuthorization will be issued for 12 months.\nE. Soft Tissue Sarcoma\n1. Initial Authorization\na. Inlyta will be approved based on both of the following criteria:\n(1) Diagnosis of alveolar soft part sarcoma (ASPS)\n-AND-\n(2) Inl",
    "sued for 12 months.\nE. Soft Tissue Sarcoma\n1. Initial Authorization\na. Inlyta will be approved based on both of the following criteria:\n(1) Diagnosis of alveolar soft part sarcoma (ASPS)\n-AND-\n(2) Inlyta will be used in combination with Keytruda (pembrolizumab)\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n3\n2. Reauthorization\na. Inlyta will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Inlyta therapy\nAuthorization will be issued for 12 months.\nF. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n3. References:\n1. Inlyta [package insert]. New York, NY: Pfizer, Inc.; July 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/professionals/drug_compendium/content/. Accessed July 30, 2024.\nProgram Prior Authorization/Notification - Inlyta (axitinib)\nChange Control\n8/2014 Annual review. Added coverage for non-clear cell kidney cancer,\nupdated formatting, Background and References.\n9/2014 Administrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n8/2015 Annual review. Added new coverage criteria for follicular, Hürthle cell\nand ",
    "g, Background and References.\n9/2014 Administrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n8/2015 Annual review. Added new coverage criteria for follicular, Hürthle cell\nand papillary carcinomas per NCCN. Increased authorization and\nreauthorization from 7 months to 12 months. Updated background and\nreferences.\n7/2016 Annual review. Revised criteria for advanced renal cell carcinoma.\nUpdated references.\n7/2017 Annual review with no change to criteria. Updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n4\n7/2018 Annual review with no change to criteria. Updated reference.\n9/2019 Updated background and criteria aligning with NCCN recommended\nfirst-line use in stage IV renal cell cancer. Added general NCCN\nrecommended review criteria.\n9/2020 Updated background without change to clinical intent. Updated\nreferences.\n9/2021 Annual review with no changes to coverage criteria. Updated\nreferences.\n9/2022 Annual review. Added criteria for NCCN recommended use in salivary\ngland tumors and alveolar soft part sarcoma (ASPS). Revised criteria\nfor renal cell carcinoma and thyroid carcinoma to align with label and\nNCCN recommendations. Added state mandate disclaimer and updated\nreferences.\n9/2023 Annual review. Changed Hürthle cell naming convention to oncocytic\ncarcinoma per NCCN standards. Updated references.\n9/2024 Annual review. Updated criteria for renal cell carcinoma per NCCN\nguidelines. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n5"
  ]
}